STTK

Shattuck Labs, Inc. (NASDAQ:STTK) is a clinical-stage biotechnology company founded in 2016 and headquartered in Austin, Texas. The company went public in October 2020 and focuses on developing innovative therapeutics for cancer and autoimmune diseases. Shattuck Labs specializes in creating fusion proteins that can simultaneously target multiple pathways in the immune system, representing a novel approach to cancer immunotherapy. The company is currently advancing its lead drug candidate through Phase 1 clinical trials while developing additional programs through its proprietary platform technology.